Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy

M S Piver, J Malfetano, T R Baker, R E Hempling
Gynecologic oncology · 1992 · doi:10.1016/0090-8258(92)90232-8 · PMID:1526515
other OA: closed public-domain-us
View on PubMed View at publisher

Abstract

Thirty-two stage IC or stage I grade 3 patients with invasive ovarian adenocarcinoma were treated with 6 months of adjuvant cisplatin-based chemotherapy. With a median follow-up of 60.5 months, there have been three (9%) recurrences. The 5-year progression-free survival was 90.5% and the 5-year survival was 93.3%.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Cisplatin Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Carcinoma Carcinoma Carcinoma Carcinoma Chemotherapy, Adjuvant Cisplatin Endometriosis Endometriosis Endometriosis Endometriosis Female Humans Neoplasm Recurrence, Local Neoplasm Staging

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
pubmed
last seen: 2026-05-13T22:11:44.647872+00:00
unpaywall
last seen: 2026-05-14T19:30:52.867331+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine